WuXi STA opened a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosage forms, this new facility adds to the company’s parenteral formulation capabilities, according to Minzhang Chen, PhD, CEO.

This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform, offering significant advantages in drug-loading, liposome particle size control, and encapsulation efficiency, continues Chen, who adds that the modular design also provides processing flexibility, enabling this platform to serve a range of manufacturing scales from 10–50 L per batch.

A contract research development and manufacturing organization (CRDMO), WuXi STA’s integrated drug product platform offers a range of services, including solid-state development, pre-formulation, formulation development, and clinical to commercial drug product manufacturing with a variety of drug delivery technologies.

“We are pleased to support our partners with this state-of-the-art LNP facility to meet the growing demand for advanced injection dosage forms,” notes Chen. “We will continue to expand our CRDMO platform’s capacity and capabilities to enable our partners to accelerate more innovative drugs to market for patients worldwide.”

Previous articleSARS-CoV-2 Enzyme’s Crystal Structure Paves Way to New Antivirals
Next articleInfection Activates Specialized Neurons to Drive Sickness Behaviors